Key result
Coronary access after TAVI with a balloon-expandable valve was required in 3.5% of patients within 3 years, achieving 100% procedural success and 97.9% clinical success for PCI.
Why the study?
As TAVI expands to younger, lower-risk patients who may require CAD treatment, post-TAVI coronary access and PCI are expected to increase, prompting evaluation of these procedures.
What is the incidence, success rate, and clinical impact of coronary access and PCI up to 3 years after TAVI with a balloon-expandable valve?
Cohort (n=1,936)
Yes
What is the incidence, success rate, and clinical impact of coronary access and PCI up to 3 years after TAVI with a balloon-expandable valve?
Coronary access and PCI after TAVI with a balloon-expandable valve are infrequently needed within 3 years but are highly successful when required.
Answers are grounded in this paper and cite their sources.
Supports high post-TAVI PCI success when needed; leaves open generalizability to other valves and longer follow-up.
Background: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to increase. The purpose of this study was to retrospectively evaluate patients who were enrolled in the SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneous coronary intervention after TAVI. Methods: Baseline characteristics and clinical outcomes of patients with or without CA up to 3 years after TAVI were compared. A Kaplan-Meier estimate with a univariate model determined the impact of CA on cardiac mortality. Results: Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%) had CA within 3 years (mean 441±332 days) after TAVI. At baseline, the logistic EuroSCORE was similar (20.2% versus 18.3%, P =0.2, CA and non-CA groups, respectively). Higher rates of coronary artery disease (76.5% versus 50.6%, P <0.001), myocardial infarction (20.6% versus 11.5%, P =0.03) and previous coronary artery bypass graft (22.1% versus 11.0%, P =0.01) were present in the CA group. In 100% of patients, CA was successfully achieved. The clinical success of percutaneous coronary intervention was 97.9%. Cardiovascular mortality was numerically higher in patients with CA than in those without CA. Conclusions: In the large SOURCE 3 European registry, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all patients. The clinical success of percutaneous coronary intervention was 97.9%. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02698956.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2020) conducted a cohort in Post-Transcatheter Aortic Valve Implantation (TAVI) (n=1,936). Coronary access (CA) after TAVI vs. No coronary access was evaluated on Coronary access success. Coronary access after TAVI with a balloon-expandable valve was required in 3.5% of patients within 3 years, achieving 100% procedural success and 97.9% clinical success for PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: